However, we showed here that both CXCL12 and β3-AR signalling are needed, and neither is sufficient for the pharmacological enhancement of myocardial infarction-induced MSC mobilisation, as mirabegron only or AMD3100 only did not result in significant increase of circulating MSCs. The gene discussed is CXCL12; the disease is myocardial infarction.